HSV infection, with its epidemiological magnitude and physical and psychological effects on the affected, is a major public health issue.
ABC believes in tackling the subset of Human Herpes Virus (HSV-1)with the only live-attenuated HSV vaccine there is in development.
This vaccine is similar to the ideology behind Zostavax, a live-attenuated Shingles vaccine that had been used successfully to vaccinate against Varicella Zoster Virus (HHV-3) for many decades.
Both of the live-attenuated HSV-1 and HSV-2 therapeutics were under research and development at Southern Illinois University in the US for almost 20 years, and have been proven in published academic studies to be 50x more effective than subunit D vaccines, the leading vaccine candidates in the industry.
The primary investigators successfully completed and replicated numerous animal model studies that demonstrated safety and immunogenicity.
*Note: For complete description of therapeutics and diagnostics with citations, please refer to ABC ICO Prospectus